Clinical Trials Browser

Breast Neoplasms

NCT06930859 2026-03-16

ELEGANCE

Recruiting

2,766 enrolled

Breast

Breast Neoplasms

NCT06830720 2026-03-03

CAROLEEN

Recruiting

3,250 enrolled

Breast

Breast Neoplasms

NCT06905301 2026-02-20

IMPULSE

Recruiting

240 enrolled

Breast

Breast Neoplasms

NCT06797531 2026-02-04

NISLEESA

Recruiting

177 enrolled

Breast

Breast Neoplasms

NCT04943497 2025-12-09

PROSPERITY

Completed

2,424 enrolled

Breast

Breast Neoplasms

NCT06148506 2025-12-05

ValerEE

Active not recruiting

376 enrolled

Breast

HR+HER2- Advanced Breast Cancer

NCT06495164 2025-11-25

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Active not recruiting

1 enrolled

Breast

Breast Neoplasms

NCT07072013 2025-07-18

IRINA

Completed

1,937 enrolled

Breast

Breast Neoplasms

NCT07008508 2025-06-06

BRAVE-Cyclin

Active not recruiting

300 enrolled

BreastClassical hematology

Breast Neoplasms, Cardiovascular Diseases, Venous Thromboembolism

NCT06805812 2025-02-03

PALMARES-2

Recruiting

3,500 enrolled

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT06075758 2025-01-14

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

Recruiting

550 enrolled

Breast

Breast Neoplasms

NCT06587789 2024-11-21

Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer

Recruiting

286 enrolled

Breast

Breast Neoplasms

NCT05569187 2022-11-08

Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer

Completed

76 enrolled

Breast

Breast Neoplasms

NCT05153135 2021-12-21

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

Completed

4,320 enrolled

Breast

Breast Neoplasms

NCT05051956 2021-09-21

Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?

Unknown

140 enrolled

Breast

Can the Geriatric Questionnaires Predict Adverse Effects in Geriatric Breast Cancer Patients Treated With Cyclin-dependent Kinase 4 and 6 Inhibitors

NCT04852081 2021-04-21

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Unknown

1,000 enrolled

Breast

Breast Neoplasms

Clinical Trials

RosaLEE

ELEGANCE

CAROLEEN

IMPULSE

NISLEESA

PROSPERITY

ValerEE

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

IRINA

BRAVE-Cyclin

PALMARES-2

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer

Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.